HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Parasitaemia and parasitic load are limited targets of the aetiological treatment to control the progression of cardiac fibrosis and chronic cardiomyopathy in Trypanosoma cruzi-infected dogs.

Abstract
It is still unclear whether the progression of acute to chronic Chagas cardiomyopathy is predominantly associated with the limited efficacy of aetiological chemotherapy, or with the pharmacological resistance profiles and pathogenicity of specific Trypanosoma cruzi strains. Thus, we tested the hypothesis that parasitic load could be a limited target of aetiological chemotherapy to prevent chronic cardiomyopathy in dogs infected by different T. cruzi strains. Animals were infected with benznidazole-susceptible (Berenice-78) and -resistant (VL-10 and AAS) strains of T. cruzi. A quantitative real-time PCR strategy was developed to comparatively quantify the parasite load of the three different strains using a single standard curve. For dogs infected with the VL-10 strain, benznidazole treatment reduced cardiac parasitism during the acute phase of infection. However, similar parasite load and collagen deposition were detected in the myocardium of treated and untreated animals in the chronic phase of the infection. In animals infected with the AAS strain, benznidazole reduced parasite load, myocarditis and type III collagen deposition in the acute phase. However, increased type III collagen deposition was verified in the chronic phase. Dogs infected with the Berenice-78 strain showed a parasitological cure and no evidence of myocardial fibrosis. Parasitic load and cardiac fibrosis presented no correlation in acute or chronic phases of T. cruzi infection. Our findings in a canine model of Chagas disease suggest that parasite burden is a limited predictor for disease progression after treatment and show that benznidazole, although not inducing parasitological cure, is able to prevent total fibrosis in the early stages of infection, as well as complete prevention of cardiac damage when it eliminates parasites at the onset of infection.
AuthorsIvo Santana Caldas, Ana Paula de Jesus Menezes, Lívia de Figueiredo Diniz, Álvaro Fernando da Silva do Nascimento, Rômulo Dias Novaes, Sérgio Caldas, Maria Terezinha Bahia
JournalActa tropica (Acta Trop) Vol. 189 Pg. 30-38 (Jan 2019) ISSN: 1873-6254 [Electronic] Netherlands
PMID30290285 (Publication Type: Journal Article)
CopyrightCopyright © 2018 Elsevier B.V. All rights reserved.
Chemical References
  • Collagen Type III
  • DNA, Protozoan
  • Nitroimidazoles
  • Trypanocidal Agents
  • benzonidazole
Topics
  • Acute Disease
  • Animals
  • Chagas Cardiomyopathy (drug therapy, parasitology, prevention & control)
  • Chronic Disease
  • Collagen Type III (metabolism)
  • DNA, Protozoan (blood)
  • Disease Models, Animal
  • Disease Progression
  • Dogs
  • Drug Resistance
  • Fibrosis
  • Heart (parasitology)
  • Myocardium (metabolism, pathology)
  • Nitroimidazoles (therapeutic use)
  • Parasite Load
  • Parasitemia (blood, drug therapy, parasitology)
  • Trypanocidal Agents (therapeutic use)
  • Trypanosoma cruzi (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: